Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

6.455 +0.015 (+0.23%)
Streaming Delayed Price Updated: 2:08 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 854,145
Open 6.350
Bid (Size) 6.450 (400)
Ask (Size) 6.460 (1,100)
Prev. Close 6.440
Today's Range 6.250 - 6.495
52wk Range 4.155 - 14.45
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗
Via Stocktwits

Performance

YTD
-11.2%
-11.2%
1 Month
+4.3%
+4.3%
3 Month
+45.4%
+45.4%
6 Month
+38.5%
+38.5%
1 Year
-13.2%
-13.2%

More News

Read More
News headline image
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
Via Benzinga
News headline image
This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday ↗
Via Benzinga
News headline image
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
Via Benzinga
News headline image
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir (VIR) Q2 Revenue Drops 61% ↗
Via The Motley Fool
News headline image
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?
Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
What is the current price of Vir Biotechnology, Inc. - Common Stock?
The current price of Vir Biotechnology, Inc. - Common Stock is 6.455
When was Vir Biotechnology, Inc. - Common Stock last traded?
The last trade of Vir Biotechnology, Inc. - Common Stock was at 11/26/25 02:08 PM ET
What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
The market capitalization of Vir Biotechnology, Inc. - Common Stock is 864.82M
How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
Vir Biotechnology, Inc. - Common Stock has 865M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.